Mesoblast Ltd ADR (MESO)

$15.81 +0.64 (4.22%)
Market Cap 2.02B
Revenue (ttm) 5.90M
Net Income (ttm) -87.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,490.85%
Debt to Equity Ratio 0.26
Volume 162,200
Avg Vol 232,440
Day's Range N/A - N/A
Shares Out 128.00M
Stochastic %K 67%
Beta 2.40
Analysts Strong Sell
Price Target $27.00

Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease,...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
Address:
55 Collins Street, Level 38, Melbourne, Australia
BarryJonathan
BarryJonathan Aug. 22 at 4:21 PM
$MESO Hot off the press .. detailed review of MSCs in prestigious Nature . Looks good to me https://www.nature.com/articles/s41392-025-02313-9
0 · Reply
Portman62
Portman62 Aug. 22 at 1:44 PM
$MESO Captain Obvious here …
0 · Reply
Pharma2005
Pharma2005 Aug. 18 at 1:56 AM
$MESO It's time to release minutes of type B July meeting with FDA.
0 · Reply
Konradkoz
Konradkoz Aug. 14 at 4:45 PM
$MESO $30 🙏
0 · Reply
curtmatson
curtmatson Aug. 14 at 3:20 AM
$MESO https://youtu.be/XP-CYdqhctY?si=-M-NtI0fZdBeAoww
0 · Reply
Mani86
Mani86 Aug. 13 at 3:21 PM
$MESO https://www.youtube.com/watch?v=XP-CYdqhctY
0 · Reply
Konradkoz
Konradkoz Aug. 4 at 4:30 PM
$MESO $30 soon
0 · Reply
Portman62
Portman62 Jul. 31 at 2:44 PM
$MESO woohooo!
0 · Reply
Bossrosswisa
Bossrosswisa Jul. 28 at 2:22 AM
$MESO $TNXP
1 · Reply
Portman62
Portman62 Jul. 25 at 1:19 AM
$MESO Invested in MESO 5 years ago, confidently I can say they are an above board company and now reaping benefits of their diligences. 🥳
0 · Reply
Latest News on MESO
Successful Commercial Launch of Ryoncil®

Jul 17, 2025, 8:38 PM EDT - 5 weeks ago

Successful Commercial Launch of Ryoncil®

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Jul 1, 2025, 8:46 AM EDT - 7 weeks ago

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Jun 30, 2025, 8:36 PM EDT - 7 weeks ago

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Jun 11, 2025, 9:24 PM EDT - 2 months ago

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

May 14, 2025, 10:57 PM EDT - 3 months ago

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

May 5, 2025, 2:44 AM EDT - 3 months ago

Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Apr 29, 2025, 8:53 PM EDT - 4 months ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Apr 28, 2025, 7:44 PM EDT - 4 months ago

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Apr 16, 2025, 9:20 PM EDT - 4 months ago

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Apr 3, 2025, 6:58 PM EDT - 5 months ago

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Apr 2, 2025, 7:15 PM EDT - 5 months ago

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

First Three Children to Commence Treatment With Ryoncil®

Mar 30, 2025, 7:39 PM EDT - 5 months ago

First Three Children to Commence Treatment With Ryoncil®

Ryoncil® is Now Available for Purchase in the United States

Mar 26, 2025, 8:19 PM EDT - 5 months ago

Ryoncil® is Now Available for Purchase in the United States

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mar 13, 2025, 7:42 PM EDT - 5 months ago

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mar 12, 2025, 7:30 AM EDT - 5 months ago

Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Feb 28, 2025, 11:38 AM EST - 6 months ago

Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Feb 26, 2025, 5:30 PM EST - 6 months ago

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Mesoblast Financial Results and Corporate Update Webcast

Feb 25, 2025, 6:13 PM EST - 6 months ago

Mesoblast Financial Results and Corporate Update Webcast

Dr. Gregory George MD PhD Joins Mesoblast Board

Feb 23, 2025, 6:33 PM EST - 6 months ago

Dr. Gregory George MD PhD Joins Mesoblast Board

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Feb 13, 2025, 6:37 PM EST - 6 months ago

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

Ryoncil® Commercial Launch Update and Product Pipeline

Jan 30, 2025, 7:11 PM EST - 7 months ago

Ryoncil® Commercial Launch Update and Product Pipeline

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Jan 30, 2025, 6:20 PM EST - 7 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 6:38 AM EST - 8 months ago

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

Dec 18, 2024, 7:08 PM EST - 8 months ago

Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Dec 18, 2024, 4:58 PM EST - 8 months ago

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

Mesoblast to be Added to Nasdaq Biotechnology Index

Dec 18, 2024, 7:30 AM EST - 8 months ago

Mesoblast to be Added to Nasdaq Biotechnology Index

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dec 12, 2024, 12:08 PM EST - 9 months ago

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

CAPR XBI

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Dec 4, 2024, 6:32 PM EST - 9 months ago

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Dec 2, 2024, 6:20 PM EST - 9 months ago

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Oct 30, 2024, 7:11 PM EDT - 10 months ago

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30, 2024, 4:24 PM EDT - 11 months ago

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Sep 29, 2024, 8:55 PM EDT - 11 months ago

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Aug 28, 2024, 9:04 PM EDT - 1 year ago

Mesoblast Limited (MESO) Q4 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Aug 28, 2024, 7:27 PM EDT - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

Jul 30, 2024, 9:13 PM EDT - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 23, 2024, 7:53 AM EDT - 1 year ago

FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Jul 21, 2024, 8:45 PM EDT - 1 year ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Jul 8, 2024, 8:37 PM EDT - 1 year ago

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Jul 1, 2024, 1:55 AM EDT - 1 year ago

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Corporate Presentation at Investor Conference

Jun 2, 2024, 8:23 PM EDT - 1 year ago

Mesoblast Corporate Presentation at Investor Conference

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

Apr 29, 2024, 9:05 PM EDT - 1 year ago

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mar 25, 2024, 10:34 PM EDT - 1 year ago

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Mar 13, 2024, 7:30 PM EDT - 1 year ago

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mar 10, 2024, 7:54 PM EDT - 1 year ago

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Feb 29, 2024, 6:07 PM EST - 1 year ago

Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Feb 28, 2024, 5:57 PM EST - 1 year ago

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Feb 14, 2024, 7:46 PM EST - 1 year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Jan 30, 2024, 9:13 PM EST - 1 year ago

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)

Jan 26, 2024, 7:03 AM EST - 1 year ago

Top 4 Health Care Stocks That May Explode This Month - Mesoblast (NASDAQ:MESO), Humana (NYSE:HUM)

HUM NEOG

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

Jan 18, 2024, 6:36 PM EST - 1 year ago

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

BarryJonathan
BarryJonathan Aug. 22 at 4:21 PM
$MESO Hot off the press .. detailed review of MSCs in prestigious Nature . Looks good to me https://www.nature.com/articles/s41392-025-02313-9
0 · Reply
Portman62
Portman62 Aug. 22 at 1:44 PM
$MESO Captain Obvious here …
0 · Reply
Pharma2005
Pharma2005 Aug. 18 at 1:56 AM
$MESO It's time to release minutes of type B July meeting with FDA.
0 · Reply
Konradkoz
Konradkoz Aug. 14 at 4:45 PM
$MESO $30 🙏
0 · Reply
curtmatson
curtmatson Aug. 14 at 3:20 AM
$MESO https://youtu.be/XP-CYdqhctY?si=-M-NtI0fZdBeAoww
0 · Reply
Mani86
Mani86 Aug. 13 at 3:21 PM
$MESO https://www.youtube.com/watch?v=XP-CYdqhctY
0 · Reply
Konradkoz
Konradkoz Aug. 4 at 4:30 PM
$MESO $30 soon
0 · Reply
Portman62
Portman62 Jul. 31 at 2:44 PM
$MESO woohooo!
0 · Reply
Bossrosswisa
Bossrosswisa Jul. 28 at 2:22 AM
$MESO $TNXP
1 · Reply
Portman62
Portman62 Jul. 25 at 1:19 AM
$MESO Invested in MESO 5 years ago, confidently I can say they are an above board company and now reaping benefits of their diligences. 🥳
0 · Reply
Mani86
Mani86 Jul. 24 at 1:37 PM
$MESO 👍
0 · Reply
Spectaculator
Spectaculator Jul. 24 at 11:11 AM
$MESO Public record shows very little institutional ownership of MESO. This is where the real upside can come from!!
2 · Reply
hots
hots Jul. 23 at 3:21 PM
$MESO Gregory George is a legend, I definitely think the increased comms and early release of the Q4 position has his mark all over it. Keep up the great work GG and Mesoblast
1 · Reply
Portman62
Portman62 Jul. 23 at 3:01 PM
$MESO hmm, are we looking at ATH by the end of the year?
0 · Reply
Mani86
Mani86 Jul. 23 at 11:42 AM
$MESO https://insightfinancenews.com/commercial-launch-of-ryoncil/?fbclid=IwY2xjawLtqaxleHRuA2FlbQIxMQBicmlkETFOTW42dm83WURDcU45Y2lNAR6i5Qj2CzmbLvCDWnWB3TWOytvTICiO7xbm_n3IiGAaFBlczM_zvPz9MUygIg_aem_7UbXwqX2v92uAwjCvdYGlw
1 · Reply
Portman62
Portman62 Jul. 22 at 1:21 PM
$MESO
0 · Reply
History101
History101 Jul. 20 at 7:10 PM
$MESO short interest, per Barron's, 6/30/2025: 2.53MM shares short (down 6% from 6/13/2025) 10.6 days to cover
0 · Reply
topstockalerts
topstockalerts Jul. 18 at 6:11 PM
$MESO buyers are stepping in.. ✅ Keep an eye for upcoming plays
0 · Reply
topstockalerts
topstockalerts Jul. 18 at 5:05 PM
$MESO not a bad place for a swing idea 💡
0 · Reply
topstockalerts
topstockalerts Jul. 18 at 4:27 PM
$MESO primed for continuation.. ✅📈 Stay tuned bulls!!
0 · Reply
TaxiBiotech_
TaxiBiotech_ Jul. 18 at 4:24 PM
$MESO Mesoblast’s Ryoncil® (remestemcel-L) commercial launch recap: First & only FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease $13.2M in Q2 gross sales (Mar 28–Jun 30) $1.6M in royalties from TEMCELL® sales in Japan 🇯🇵 Now covered by Medicare/Medicaid 7-year orphan drug exclusivity + 12-year BLA protection 25 US transplant centers onboarded, targeting 45 🏥 #Biotech #CellTherapy
1 · Reply
ChazzyTrades
ChazzyTrades Jul. 18 at 3:50 PM
$MESO ez money
1 · Reply